Related references
Note: Only part of the references are listed.Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
Helena Boutzen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features
V. I. Gaidzik et al.
LEUKEMIA (2016)
Targeted Therapy Alone for Acute Promyelocytic Leukemia
Francesco Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells
Maria Paola Martelli et al.
BLOOD (2015)
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells
Hiba El Hajj et al.
BLOOD (2015)
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
Peter Paschka et al.
HAEMATOLOGICA (2015)
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group
Peter Paschka et al.
HAEMATOLOGICA (2015)
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
Michela Tassara et al.
BLOOD (2014)
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG)
Verena I. Gaidzik et al.
BLOOD (2013)
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
F. Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm-Combined Prospective Analysis by the German AML Intergroup
Thomas Buechner et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1
Ramesh Balusu et al.
BLOOD (2011)
Eliciting Mucosal Immunity
Wayne I. Lencer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
Alan K. Burnett et al.
BLOOD (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A
Richard F. Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B
Richard F. Schlenk et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
Alan K. Burnett et al.
CANCER (2007)
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
Donald W. Milligan et al.
BLOOD (2006)
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
RF Schlenk et al.
LEUKEMIA (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cytokine-regulated expression of survivin in myeloid leukemia
BZ Carter et al.
BLOOD (2001)
Share Paper
